Medical Termination of PregnancyNCT02171845
Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans
An observational study of Medical Termination of Pregnancy and Voluntary Termination of Pregnancy, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
This is a single-centre study over 36 months for the inclusion of 30 patients. The selection and inclusion of patients will take place according to the criterion of Medical Termination of Pregnancy at 4 different gestational ages (8-12 weeks of gestation (WG)), 13-16 WG, 17-23 WG and 25-35 WG. Read more about this study
- Who is it for?
- Ages 10 to 37 weeks, men only
- Conditions the study is for
- Medical Termination of Pregnancy, Voluntary Termination of Pregnancy
- What is being tested?
- surgical biopsies
- How many people
- 8 participants
- Where
- 1 siteFrance
- Study dates
- 29 Jan 2014to 25 Aug 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 37 weeks
- Men only
- No healthy volunteers
- Child
Study population: Male foetuses of 10 to 37 weeks of amenorrhea obtained following medical termination of pregnancy or voluntary termination of pregnancy.
Who may be able to join
- Couple or mother who has provided written informed consent
- Foetus between 10 and 37 weeks of amenorrhea (WA)
- Male foetus
- Foetus obtained following medical termination of pregnancy or voluntary termination of pregnancy
Who cannot join
- persons without national health insurance cover
- foetus presenting aneuploidy
- foetus presenting a malformation of the genital organs
Trial locations and contacts
1 site in 1 country.
About this study
This is a single-centre study over 36 months for the inclusion of 30 patients. The selection and inclusion of patients will take place according to the criterion of Medical Termination of Pregnancy at 4 different gestational ages (8-12 weeks of gestation (WG)), 13-16 WG, 17-23 WG and 25-35 WG. The tissue analysed will principally be the gonads, other somatic tissue will also be systematically harvested in parallel (liver and psoas muscle) for control purposes. The gonads will be subjected to molecular biology analyses destined to quantify the expression of transposons and their inhibitors.
- Being tested
- surgical biopsies
- Keywords
- Male foetuses of 10 to 37 weeks
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
surgical biopsiesOther
| Study group | Role | What they receive |
|---|---|---|
| Foetus | Not described Receives: Other: surgical biopsies |
What is being measured
The primary outcome is the main question the study is designed to answer.
Spatio-temporal analysis of the activity of TEs by RT-qPCR and immunostaining
Measured: Baselines
Secondary outcomes (1)
Promoter methylation profile by pyrosequencing
Measured: Baselines
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2014 (estimated)
- Study start29 Jan 2014
- Primary completion25 Aug 2016
- Study completion25 Aug 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medical Termination of PregnancyStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire DijonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02171845
- Sponsor's protocol ID
- FAUQUE ANR 2011
- Status last verified
- Oct 2026
- First submitted
- 18 Jun 2014
- Last updated
- 23 Oct 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans
- ClinicalTrials.gov ID
- NCT02171845
- Acronym / sponsor ID
- FAUQUE ANR 2011
- Keywords
- Male foetuses of 10 to 37 weeks
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 29 Jan 2014 (actual)
- Primary completion
- 25 Aug 2016 (actual)
- Study completion
- 25 Aug 2016 (actual)
- First posted
- 24 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-centre study over 36 months for the inclusion of 30 patients. The selection and inclusion of patients will take place according to the criterion of Medical Termination of Pregnancy at 4 different gestational ages (8-12 weeks of gestation (WG)), 13-16 WG, 17-23 WG and 25-35 WG. The tissue analysed will principally be the gonads, other somatic tissue will also be systematically harvested in parallel (liver and psoas muscle) for control purposes. The gonads will be subjected to molecular biology analyses destined to quantify the expression of transposons and their inhibitors.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Foetus | – | Other: surgical biopsies |
Who may qualify
- Ages
- 10 to 37 weeks
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Male foetuses of 10 to 37 weeks of amenorrhea obtained following medical termination of pregnancy or voluntary termination of pregnancy.
Key inclusion criteria (4 listed)
- Couple or mother who has provided written informed consent
- Foetus between 10 and 37 weeks of amenorrhea (WA)
- Male foetus
- Foetus obtained following medical termination of pregnancy or voluntary termination of pregnancy
Key exclusion criteria (3 listed)
- persons without national health insurance cover
- foetus presenting aneuploidy
- foetus presenting a malformation of the genital organs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| surgical biopsies | Other | Foetus |
Primary outcome
Spatio-temporal analysis of the activity of TEs by RT-qPCR and immunostaining
Time frame: Baselines
1 secondary outcome
Promoter methylation profile by pyrosequencing
Time frame: Baselines
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
Related trials for Medical Termination of Pregnancy
Recruiting
Randomized Study of a Dematerialized Management for Post-Emergency Gynecological Follow-Up
Genital Diseases, Female, Ectopic Pregnancy
Not yet recruitingObservational study
Predictors of Successful Office Operative Hysteroscopy Using a Mini-Resectoscope
Retained Products of Conception, Hysteroscopy
Not yet recruiting
'No-test' Tele-abortion: a Multi-centre Randomised Controlled Trial
Medical Abortion
Not yet recruiting
GPT-Based Digital Assistant Support During Treatment for Induced Abortion or Missed Abortion
Missed Abortion, Early Pregnancy Loss
Not yet recruitingPhase 1/2
Second Trimester Abortion With Letrozole and Misoprostol Compared to Misoprostol Alone
Abortion Induced Complicated, Abortion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Medical Termination of Pregnancy and Voluntary Termination of Pregnancy, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Spatio-temporal analysis of the activity of TEs by RT-qPCR and immunostaining (time frame: Baselines). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.